Fig. 1: Interaction of lymphopenia with MDS clinical and molecular features, and prognostic impact.
From: Lymphopenia confers poorer prognosis in Myelodysplastic Syndromes with very low and low IPSS-M
A Prevalence of lymphopenia (defined as absolute lymphocyte count (ALC) < 1.5 G/L) in IPSS-M subgroups; (B) ALC in IPSS-M subgroups (threshold of 1.5 G/L is indicated with a black bar); (C) Mutational landscape of most commonly mutated genes in MDS patients with or without lymphopenia; **p < 0.01; (D) Impact of lymphopenia on MDS patients’ overall survival (OS) according to IPSS-M strata; (E): Impact of lymphopenia on MDS patients’ leukemia-free survival (LFS) according to IPSS-M strata.
